SEC
SlamSEC
SearchBrowseEarnings

Longeveron Inc.

Nasdaq:LGVN
Pharmaceutical Preparations·MIAMI, FL
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Revenue
$709,000
FY 2024
Adj. EBITDA
-$20.3M
-2867.3% margin
FY 2024
Net Income
-$21.4M
-3020.2% margin
FY 2024
EPS (Diluted)
-$10.22
FY 2024
Stock Price
$0.48
-2.5%
2026-03-06
52W Range
$0.47 – $1.92
P/E Ratio
-0.0x
Market Cap
—
Cash
$4.9M
FY 2024
Total Debt
$311,000
FY 2021
Net Cash
$4.6M
FY 2021
Enterprise Value
—
Debt / EBITDA
0.2x
FY 2024
EV / EBITDA
—
Employees
—